Description: Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology. Its products include XIAFLEX, a non-surgical treatment for Peyronie's Disease for adult men with a collagen plaque and a penile curvature deformity; and Dupuytren's Contracture for adult patients with an abnormal buildup of collagen in the fingers that limits or disables hand function. This segment is also developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The Sterile Injectable segment offers ADRENALIN, a non-selective alpha- and beta-adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; and VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The Generic Pharmaceuticals segment provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays, as well as products that treat and manage a rage of medical conditions. The International Pharmaceuticals segment sells a range of specialty pharmaceutical products primarily to customers in Canada. Its principal products serve various therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation, as well as over-the-counter products. The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.
Home Page: www.endo.com
1400 Atwater Drive
Malvern,
PA
19355
United States
Phone:
484 216 0000
Officers
| Name | Title |
|---|---|
| Mr. Mark T. Bradley | Executive VP & CFO |
| Mr. Matthew Joseph Maletta | Executive VP, Chief Legal Officer & Company Secretary |
| Mr. Patrick A. Barry | Executive VP & President of Global Commercial Operations |
| Dr. James Patrick Tursi M.D. | Executive Vice President of Global Research & Development |
| Mr. Scott A. Hirsch | Interim Chief Executive Officer & Director |
| Mr. Frank B. Raciti | VP, Controller & Chief Accounting Officer |
| Ms. Cheryl Stouch | Senior VP of Information Technology & Chief Information Officer |
| Ms. Laure E. Park | Senior Vice President of Investor Relations & Corporate Affairs |
| Ms. Susan Williamson CPA | Senior VP & Chief Compliance Officer |
| Ms. Tracy Basso | Chief Human Resources Officer |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | |
| Full Time Employees: | 2931 |